Indraprastha Medical Corporation
- Market cap
- ₹ 2,765 Cr.
- P/E
- 15.4x
- P/B
- 3.78x
- 52-week range
- 293.65 – 640.85
- ROE
- 27%
- ROCE
- 36%
- Dividend yield
- 1.3%
- Debt / equity
- 0.05
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Indraprastha Medical Corporation Limited is an India-based company engaged in the healthcare business. The business activities of the Company are running and operating hospitals, which include Indraprastha Apollo Hospitals and Apollo Hospitals. Indraprastha Apollo Hospitals is a multi-specialty tertiary acute care hospital with approximately 710 beds and is spread over 15 acres and has a built-up area of over 600,000 square feet. It has approximately 52 specialties under one roof with the major specialties being anesthesia, cardiology, cardiac surgery, cancer, pediatrics, critical care, emergency care, fetal medicine, gastroenterology and hepatology, obstetrics & gynecology, interventional radiology, IVF, liver and kidney transplant, nuclear medicine, nephrology, neurosciences, ophthalmology, orthopedics, otolaryngology (ENT), pediatrics, pediatric surgery, psychiatry and clinical psychology, rheumatology, spine surgery, urology and andrology and vascular and endovascular surgery.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Indraprastha Medical Corporation against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)15.4 against a typical 48.9: cheaper than most peers (1st = cheapest).4th of 40
- Sales growth+11.2% against a typical +21.1% from a year earlier.28th of 34
- Profit growth+9.8% against a typical +13% from a year earlier.17th of 31
- Share price, 3 months−13.4% against a typical −10.9%.20th of 34
- Size₹ 2,765 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).15th of 36
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA | Stable | 26 May 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 26 May 2026 | Reaffirmed | [ICRA]AA | — | ICRA | ₹ 162.5 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 6 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 12 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 3 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 1 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 6 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 16 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 317 | 306 | 315 | 348 | 350 | 325 | 334 | 365 | 381 | 372 | 365 | 406 |
| Expenses | 267 | 259 | 266 | 281 | 286 | 273 | 272 | 292 | 310 | 310 | 304 | 326 |
| Operating Profit | 50 | 47 | 48 | 67 | 64 | 52 | 61 | 73 | 71 | 62 | 61 | 80 |
| OPM % | 16% | 15% | 15% | 19% | 18% | 16% | 18% | 20% | 19% | 17% | 17% | 20% |
| Other Income | 4 | 4 | 5 | 5 | 6 | 5 | 6 | 7 | 7 | 7 | 7 | 8 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 2 |
| Depreciation | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 10 | 11 | 11 | 11 | 12 |
| Profit before tax | 44 | 41 | 42 | 60 | 57 | 45 | 55 | 68 | 66 | 56 | 55 | 75 |
| Tax % | 25% | 28% | 25% | 25% | 26% | 26% | 26% | 25% | 25% | 27% | 24% | 25% |
| Net Profit | 33 | 29 | 31 | 45 | 42 | 33 | 41 | 51 | 49 | 41 | 42 | 56 |
| EPS in Rs | 3.58 | 3.21 | 3.4 | 4.88 | 4.63 | 3.58 | 4.47 | 5.61 | 5.4 | 4.47 | 4.55 | 6.09 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 7%
- 5 Years
- 19%
- 3 Years
- 11%
- TTM
- 11%
- 10 Years
- 22%
- 5 Years
- 132%
- 3 Years
- 28%
- TTM
- 12%
- 10 Years
- 21%
- 5 Years
- 37%
- 3 Years
- 31%
- TTM
- —
- 10 Years
- 21%
- 5 Years
- 27%
- 3 Years
- 29%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Indraprastha Medical Corporation | ₹ 314.20 | ₹ 2,765 Cr. | 15.4x | 3.8x | 27% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- C. P. Tyagi
- Chief Financial Officer
- Priya Ranjan
- Company Secretary, Compliance Officer, Associate Vice President - Corporate Affairs and Legal
- Shivakumar Pattabhiraman
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.